Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) EBT Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBT Margin for 1 consecutive years, with 116256.64% as the latest value for Q2 2025.

  • On a quarterly basis, EBT Margin changed N/A to 116256.64% in Q2 2025 year-over-year; TTM through Dec 2025 was 82.44%, a N/A change, with the full-year FY2025 number at 45.44%, changed N/A from a year prior.
  • EBT Margin was 116256.64% for Q2 2025 at Neuphoria Therapeutics, up from 74.54% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 116256.64% in Q2 2025 to a low of 74.54% in Q1 2025.